Image

Global Dengue Vaccine Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Global Dengue Vaccine Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Dec 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Dengue Vaccine Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 0.53 USD Billion
Diagram Market Size (Forecast Year) USD 1.28 USD Billion
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Dengue Vaccine Market, By Type (Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine), Treatment (Diuretic, Anti-Allergic, Blood Thinners, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Dengue Vaccine Market

Dengue Vaccine Market Analysis and Size

Dengue vaccine is only recommended for those who previously suffered from dengue fever. It is given as three injections all over a year. A vaccine to prevent dengue (Dengvaxia) has been licensed and is available in some countries for people between the ages of 9-45. The Developing Countries Vaccine Manufacturers Network (DCVMN) is gaining much popularity for its increasing capacity and willingness to advance vaccine clinical development effectively.  

Data Bridge Market Research analyses a growth rate in the dengue vaccine market in the forecast period 2023-2030. The expected CAGR of the dengue vaccine market tends to be around 11.7% in the mentioned forecast period. The market was valued at USD 0.53 billion in 2022, and it would grow up to USD 1.28 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Dengue Vaccine Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine), Treatment (Diuretic, Anti-Allergic, Blood Thinners, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), GSK plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Takeda Pharmaceutical Company Limited (Japan), BIO-MED (India), Intercept Pharmaceuticals, Inc (U.K.), Emcure Pharmaceuticals Limited (India), Changchun BCHT Biotechnology Co. (China), Novo Medi Sciences (India)

Market Opportunities

  • Increased Initiatives by Several Organizations

Market Definition

Dengue is a mosquito-borne tropical disease that is caused by dengue virus. The symptoms for this condition usually begin 3 to 14 days post infection. Symptoms include vomiting, high fever, muscle & joint pain, headache, and a characteristic skin rash. The World Health Organization (WHO) recommends that the vaccine be only given to people who have confirmed a history of dengue virus infection. 

Dengue Vaccine Market Dynamics

Drivers

  • Increasing Incidence of Dengue

Growing incidence of dengue is projected to boost growth of the dengue vaccine market during the forecast period. For instance, as per the Pan American Health Organization, 1,191,815 cases of dengue were stated, wherein 546,589 were laboratory-confirmed and 5,599 were classified as severe dengue in the region of the Americas, between epidemiological week 1 and 22 of 2019. Thus, this boosts the demand for vaccines.

  • Growing R&D Activities

The commitment to R&D for vaccine development is one of the most essential strategies to obtain a competitive edge in the dengue vaccines market. Persistent research holds promising potential for the development of next-gen dengue, malaria, and tuberculosis vaccines. Several R&D of live attenuated vaccines is also expected to help in the growth of the market. For instance, in May 2019, the U.S. FDA approved Dengvaxia used for the prevention of dengue disease is caused by all dengue virus serotypes. It is a live attenuated tetravalent chimeric vaccine which is made using recombinant DNA technology. Additionally, Panacea Biotec, a global generic and specialty pharmaceutical and vaccine maker registered in India, has successfully completed phase I/II study of its novel tetravalent recombinant chimeric dengue candidate vaccine DengiAll.

Opportunities

  • Increased Initiatives by Several Organizations

There are certain organizations that led to the development of several vaccines which is useful for eliminating dengue. For instance, the Department of Biotechnology in India is directing concerted efforts to reinforce vaccine R&D through its Vaccine Action Program. As part of this initiative, the Indo-US Vaccine Action Program (VAP) was initiated in 2017. This is a bilateral program that is developed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) within the Department of Health and Human Services, United States and the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India, in conjunction with the Human Immunology Project Consortium (HIPC).

Restraints/Challenges

  • Lack of Understanding the Differences

The increasing inability to differentiate dengue fever from other febrile diseases is projected to impede growth of the market. For instance, the symptoms of mosquito-borne diseases such as Zika, chikungunya virus infection, and dengue fever are very identical, which makes the diagnosis difficult. Additionally, lack of understanding of the pathophysiology of dengue infection and the lack of specific animal models is anticipated to hamper growth of the market.

  • Unavailability of Vaccinations

There is wide unavailability of vaccines that is obstructing the market growth. Vaccination for dengue is not available in many under developed regions. And thus, it gets the population out there to deal with the outbreak. Therefore, in a way, it impedes the market growth.

This dengue vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the dengue vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development:

  • In 2021, Takeda Pharmaceutical Company Limited announced the approval of its TAK-003 dengue vaccine candidate by the European Medicines Agency (EMA), which is currently under investigation for the prevention of any outbreaks in individuals aged 4 to 60 years. The company also intends to apply for regulatory approvals in Argentina, Brazil, Columbia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand through 2021.

Global Dengue Vaccine Market Scope

The dengue vaccine market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Live Attenuated Vaccine
  • Chimeric Live Attenuated Vaccine
  • Inactivated Vaccine
  • Subunit Vaccine
  • Nucleic Acid Based Vaccine

Treatment

  • Diuretic
  • Chlorothiazide
  • Chlorthalidone
  • Hydrochlorothiazide
  • Indapamide
  • Anti-Allergic
  • Cetirizine
  • Desloratadine
  • Fexofenadine
  • Blood Thinners
  • Apixaban
  • Dabigatran
  • Edoxaban
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Dengue Vaccine Market Regional Analysis/Insights

The dengue vaccine market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the dengue vaccine market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing positive growth for the dengue vaccine market throughout the forecast period due to the presence of major key players and the increased prevalence of dengue.

Asia-Pacific dominates the market due to increase in government expenditure for development of better healthcare infrastructures within the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Dengue Vaccine Market Share Analysis

The dengue vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dengue vaccine market

Key players operating in the dengue vaccine market include:

  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • GSK plc (U.K.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • BIO-MED (India)
  • Intercept Pharmaceuticals, Inc (U.K.)
  • Emcure Pharmaceuticals Limited (India)
  • Changchun BCHT Biotechnology Co. (China)
  • Novo Medi Sciences (India)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The dengue vaccine market size will be worth USD 1.28 billion by 2030.
The growth rate of the dengue vaccine market is 11.7% in the forecast by 2030.
Major companies in the dengue vaccine market are Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), GSK plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Takeda Pharmaceutical Company Limited (Japan), etc.
Type, treatment, route of administration, distribution channel, and end-user are the factors on which the dengue vaccine market research is based.
Growing incidence of dengue & growing R&D activities are the growth drivers of the dengue vaccine market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials